Impact of acute chest syndrome on lung function of children with sickle cell disease

Area of Science:

• Pediatric Pulmonology
• Hematology
• Cardiopulmonary Research

Background:

• Sickle cell disease (SCD) is a genetic blood disorder with significant pulmonary complications.
• Acute chest syndrome (ACS) is a common and serious complication in children with SCD, often requiring hospitalization.
• The long-term impact of ACS on lung function in pediatric SCD patients remains an area of active investigation.

Purpose of the Study:

• To investigate the hypothesis that children with SCD who have experienced an ACS hospitalization exhibit diminished lung function compared to those without ACS.
• To identify specific pulmonary function parameters affected by ACS episodes in pediatric SCD.

Main Methods:

• A comparative study involving 20 children with SCD and a history of ACS hospitalization versus 20 age-matched controls without ACS.
• Pulmonary function tests (PFTs) including spirometry (FEV1, FVC, FEV1/FVC, PEF, FEF25-75), airway resistance (Raw), and lung volumes were performed.
• Assessment included pre- and post-bronchodilator responses in a subset of participants.

Main Results:

• Children with SCD and ACS history demonstrated significantly higher airway resistance (Raw), total lung capacity (TLC), and residual volume (RV) compared to controls.
• Pre-bronchodilator, lower forced expiratory flow at 25% (FEF25) and 75% (FEF75) of FVC were observed in the ACS group.
• Post-bronchodilator, the ACS group showed a lower mean FEV1/FVC ratio and FEF75, indicating persistent obstructive changes.

Conclusions:

• Pediatric patients with SCD who have experienced ACS hospitalization exhibit distinct alterations in lung function.
• The findings support the hypothesis that ACS episodes contribute to increased airway obstruction in children with SCD.
• These results underscore the importance of monitoring pulmonary health in pediatric SCD patients with a history of ACS.